Analyst Price Targets — ARQT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 11:40 am | Doug Tsao | H.C. Wainwright | $34.00 | $27.01 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $34 at H.C. Wainwright |
| November 28, 2025 11:32 am | Uy Ear | Mizuho Securities | $37.00 | $30.96 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $37 at Mizuho |
| October 30, 2025 11:29 am | Richard Law | Goldman Sachs | $29.00 | $25.41 | TheFly | Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs |
| October 29, 2025 10:20 am | Douglas Tsao | H.C. Wainwright | $30.00 | $24.95 | TheFly | Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright |
| October 29, 2025 10:11 am | Uy Ear | Mizuho Securities | $32.00 | $24.95 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $32 at Mizuho |
| March 11, 2025 5:59 pm | — | Jefferies | $19.00 | $15.49 | TheFly | Arcutis Biotherapeutics price target raised to $19 from $16 at Jefferies |
| December 30, 2024 11:08 am | Douglas Tsao | H.C. Wainwright | $19.00 | $14.20 | TheFly | Arcutis Biotherapeutics initiated with a Buy at H.C. Wainwright |
| May 15, 2024 7:15 am | Serge Belanger | Needham | $18.00 | $8.13 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Needham |
| May 15, 2024 5:18 am | Uy Ear | Mizuho Securities | $18.00 | $8.13 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Mizuho |
| January 2, 2024 4:07 pm | — | Mizuho Securities | $8.00 | $3.43 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $8 at Mizuho Securities, Upgraded to Buy |
Latest News for ARQT
Quantum Biopharma (NASDAQ: QNTM - Get Free Report) and Arcutis Biotherapeutics (NASDAQ: ARQT - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation. Profitability This table compares Quantum Biopharma and Arcutis
WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after the U.S. financial markets close.
A director of Arcutis Biotherapeutics reported selling 10,000 shares for a total transaction value of $239,000 on April 1, 2026. This sale represented 20.10% of Howard G.
JPMorgan Chase and Co. decreased its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) by 81.6% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 100,794 shares of the company's stock after selling 447,995 shares during the period. JPMorgan Chase and Co. owned
Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (Nasdaq: INCY) supporting the launch of OPZELURA®
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARQT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.